Toward integrative cancer immunotherapy: targeting the tumor microenvironment

Hdl Handle:
http://hdl.handle.net/10675.2/788
Title:
Toward integrative cancer immunotherapy: targeting the tumor microenvironment
Authors:
Emens, Leisha A; Silverstein, Samuel C; Khleif, Samir; Marincola, Francesco M; Galon, Jérôme
Abstract:
The development of cancer has historically been attributed to genomic alterations of normal host cells. Accordingly, the aim of most traditional cancer therapies has been to destroy the transformed cells themselves. There is now widespread appreciation that the progressive growth and metastatic spread of cancer cells requires the cooperation of normal host cells (endothelial cells, fibroblasts, other mesenchymal cells, and immune cells), both local to, and at sites distant from, the site at which malignant transformation occurs. It is the balance of these cellular interactions that both determines the natural history of the cancer, and influences its response to therapy. This active tumor-host dynamic has stimulated interest in the tumor microenvironment as a key target for both cancer diagnosis and therapy. Recent data has demonstrated both that the presence of CD8+ T cells within a tumor is associated with a good prognosis, and that the eradication of all malignantly transformed cells within a tumor requires that the intra-tumoral concentration of cytolytically active CD8+ effector T cells remain above a critical concentration until every tumor cell has been killed. These findings have stimulated two initiatives in the field of cancer immunotherapy that focus on the tumor microenvironment. The first is the development of the immune score as part of the routine diagnostic and prognostic evaluation of human cancers, and the second is the development of combinatorial immune-based therapies that reduce tumor-associated immune suppression to unleash pre-existing or therapeutically-induced tumor immunity. In support of these efforts, the Society for the Immunotherapy of Cancer (SITC) is sponsoring a workshop entitled "Focus on the Target: The Tumor Microenvironment" to be held October 24-25, 2012 in Bethesda, Maryland. This meeting should support development of the immune score, and result in a position paper highlighting opportunities for the development of integrative cancer immunotherapies that sculpt the tumor microenvironment to promote definitive tumor rejection.
Citation:
J Transl Med. 2012 Apr 10; 10:70
Issue Date:
10-Apr-2012
URI:
http://hdl.handle.net/10675.2/788
DOI:
10.1186/1479-5876-10-70
PubMed ID:
22490302
PubMed Central ID:
PMC3341195
Type:
Article
ISSN:
1479-5876
Appears in Collections:
Georgia Cancer Center: Faculty Research and Presentations

Full metadata record

DC FieldValue Language
dc.contributor.authorEmens, Leisha Aen_US
dc.contributor.authorSilverstein, Samuel Cen_US
dc.contributor.authorKhleif, Samiren_US
dc.contributor.authorMarincola, Francesco Men_US
dc.contributor.authorGalon, Jérômeen_US
dc.date.accessioned2012-10-26T20:30:44Z-
dc.date.available2012-10-26T20:30:44Z-
dc.date.issued2012-04-10en_US
dc.identifier.citationJ Transl Med. 2012 Apr 10; 10:70en_US
dc.identifier.issn1479-5876en_US
dc.identifier.pmid22490302en_US
dc.identifier.doi10.1186/1479-5876-10-70en_US
dc.identifier.urihttp://hdl.handle.net/10675.2/788-
dc.description.abstractThe development of cancer has historically been attributed to genomic alterations of normal host cells. Accordingly, the aim of most traditional cancer therapies has been to destroy the transformed cells themselves. There is now widespread appreciation that the progressive growth and metastatic spread of cancer cells requires the cooperation of normal host cells (endothelial cells, fibroblasts, other mesenchymal cells, and immune cells), both local to, and at sites distant from, the site at which malignant transformation occurs. It is the balance of these cellular interactions that both determines the natural history of the cancer, and influences its response to therapy. This active tumor-host dynamic has stimulated interest in the tumor microenvironment as a key target for both cancer diagnosis and therapy. Recent data has demonstrated both that the presence of CD8+ T cells within a tumor is associated with a good prognosis, and that the eradication of all malignantly transformed cells within a tumor requires that the intra-tumoral concentration of cytolytically active CD8+ effector T cells remain above a critical concentration until every tumor cell has been killed. These findings have stimulated two initiatives in the field of cancer immunotherapy that focus on the tumor microenvironment. The first is the development of the immune score as part of the routine diagnostic and prognostic evaluation of human cancers, and the second is the development of combinatorial immune-based therapies that reduce tumor-associated immune suppression to unleash pre-existing or therapeutically-induced tumor immunity. In support of these efforts, the Society for the Immunotherapy of Cancer (SITC) is sponsoring a workshop entitled "Focus on the Target: The Tumor Microenvironment" to be held October 24-25, 2012 in Bethesda, Maryland. This meeting should support development of the immune score, and result in a position paper highlighting opportunities for the development of integrative cancer immunotherapies that sculpt the tumor microenvironment to promote definitive tumor rejection.en_US
dc.rightsCopyright ©2012 Emens et al; licensee BioMed Central Ltd.en_US
dc.subjectEditorialen_US
dc.titleToward integrative cancer immunotherapy: targeting the tumor microenvironmenten_US
dc.typeArticleen_US
dc.identifier.pmcidPMC3341195en_US
dc.contributor.corporatenameGHSU Cancer Center-

Related articles on PubMed

All Items in Scholarly Commons are protected by copyright, with all rights reserved, unless otherwise indicated.